A systematic review and meta-analysis suggests that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may be associated with protective effects for patients with COVID-19. The analysis included 52 studies that evaluated clinical outcomes among 101 949 total patients, of whom 26.0% were receiving ACEIs or ARBs. When adjusted for covariates, significant reductions in the risk of death (adjusted odds ratio [aOR], 0.57) and severe adverse events (AEs, aOR, 0.68) were found. Unadjusted and adjusted analyses of a subgroup of patients with high blood pressure indicated decreases in the risk of death (unadjusted OR, 0.66; aOR, 0.51) and severe AEs (unadjusted OR, 0.70; aOR, 0.55). The findings are consistent with previous meta-analysis in patients with high blood pressure, extend to patients with multiple mixed comorbidities, and support the recommendations of medical societies to continue receiving ACEIs and ARBs for patients with COVID-19. Source: https://jamanetwork.com/
Restricting sugar intake during the first 1,000 days from conception was associated with a lower…
Incidental coronary artery calcium (CAC) identified on routine nongated chest CT scans predicts future coronary…
The burden of modifiable cardiovascular risk factors—not just the total number of risk factors—is strongly…
Higher blood levels of the gut microbiome-derived metabolite trimethylamine N-oxide (TMAO) were independently associated with…
Moderate consumption of naturally caffeinated beverages, particularly coffee, is generally associated with a lower risk…
To reduce the risk of cognitive decline and/or dementia specifically, the WHO just released updated…
This website uses cookies.